Uterine papillary serous cancer: A review of the literature

被引:99
作者
del Carmen, Marcela G. [1 ]
Birrer, Michael [2 ]
Schorge, John O. [1 ]
机构
[1] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gynecol Oncol Vincent Obstet & Gynecol, Boston, MA 02114 USA
[2] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Med Oncol, Boston, MA 02114 USA
关键词
Uterine serous cancer; Surgery; Chemotherapy; Radiation; ENDOMETRIAL GLANDULAR DYSPLASIA; PLATINUM-BASED CHEMOTHERAPY; RANDOMIZED PHASE-III; POSITRON-EMISSION-TOMOGRAPHY; WHOLE ABDOMINAL RADIOTHERAPY; POLYMERASE-CHAIN-REACTION; CLINICAL STAGE-I; CLEAR-CELL; BREAST-CANCER; NEOADJUVANT CHEMOTHERAPY;
D O I
10.1016/j.ygyno.2012.09.012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. Uterine papillary serous carcinoma (UPSC) represents a distinct subtype of endometrial cancer. UPSC is less common than endometrioid carcinoma (ECC) but accounts for a disproportionate number of uterine cancer related deaths. This article critically reviews the literature pertinent to the pathology, pathogenesis, diagnosis, management, and outcome of patients with UPSC. Methods. MEDLINE was searched for all research articles published in English between January 1, 1967-January 1, 2012 which reported on patients diagnosed with UPSC. Given the rarity of this tumor, studies were not limited by design or number of reported patients. Results. UPSC represents a histologically aggressive subtype of endometrial cancer. It commonly presents with extra uterine disease involvement which can be identified by comprehensive surgical staging. Optimal cytoreduction and systemic platinum/taxane-based adjuvant therapy appear to confer a survival advantage. Conclusions. UPSC is a biologically distinct entity, different from ECC. Future studies should explore the role of targeted therapies in the management of UPSC. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:651 / 661
页数:11
相关论文
共 145 条
  • [1] Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose in oncology Part II.: The clinical value in detecting and staging primary tumours
    Ak, I
    Stokkel, MPM
    Pauwels, EKJ
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2000, 126 (10) : 560 - 574
  • [2] Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer
    Akram, T
    Maseelall, P
    Fanning, J
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2005, 192 (05) : 1365 - 1367
  • [3] ENDOMETRIAL INTRAEPITHELIAL CARCINOMA - A DISTINCTIVE LESION SPECIFICALLY ASSOCIATED WITH TUMORS DISPLAYING SEROUS DIFFERENTIATION
    AMBROS, RA
    SHERMAN, ME
    ZAHN, CM
    BITTERMAN, P
    KURMAN, RJ
    [J]. HUMAN PATHOLOGY, 1995, 26 (11) : 1260 - 1267
  • [4] [Anonymous], GYNECOL ONCOL
  • [5] TAMOXIFEN USE IN BREAST-CANCER PATIENTS WHO SUBSEQUENTLY DEVELOP CORPUS CANCER IS NOT ASSOCIATED WITH A HIGHER INCIDENCE OF ADVERSE HISTOLOGIC FEATURES
    BARAKAT, RR
    WONG, G
    CURTIN, JP
    VLAMIS, V
    HOSKINS, WJ
    [J]. GYNECOLOGIC ONCOLOGY, 1994, 55 (02) : 164 - 168
  • [6] Risk and prognosis of endometrial cancer after tamoxifen for breast cancer
    Bergman, L
    Beelen, MLR
    Gallee, MPW
    Hollema, H
    Benraadt, J
    van Leeuwen, FE
    [J]. LANCET, 2000, 356 (9233) : 881 - 887
  • [7] Body size in relation to cancer of the uterine corpus in 1 million Norwegian women
    Bjorge, Tone
    Engeland, Anders
    Tretli, Steinar
    Weiderpass, Elisabete
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2007, 120 (02) : 378 - 383
  • [8] 2 PATHOGENETIC TYPES OF ENDOMETRIAL CARCINOMA
    BOKHMAN, JV
    [J]. GYNECOLOGIC ONCOLOGY, 1983, 15 (01) : 10 - 17
  • [9] Management of women with uterine papillary serous cancer: A Society of Gynecologic Oncology (SGO) review
    Boruta, David M., II
    Gehrig, Paola A.
    Fader, Amanda Nickles
    Olawaiye, Alexander B.
    [J]. GYNECOLOGIC ONCOLOGY, 2009, 115 (01) : 142 - 153
  • [10] Uterine serous and Grade 3 endometrioid carcinomas - Is there a survival difference?
    Boruta, DM
    Gehrig, PA
    Groben, PA
    Bae-Jump, V
    Boggess, JF
    Fowler, WC
    Van Le, L
    [J]. CANCER, 2004, 101 (10) : 2214 - 2221